Contineum Therapeutics (CTNM) Corporate presentation summary

Strategic focus and pipeline overview

• Advancing internally developed therapies for neuroscience, inflammation, and immunology indications, targeting large markets with unmet needs such as IPF, MDD, MS, and chronic pain.

• Multiple clinical programs with validated targets (LPA1R, M1R) and a partnership with Johnson & Johnson for PIPE-307 in RRMS and MDD.

• Projected cash runway through mid-2029 to support key milestones.

PIPE-791: Idiopathic pulmonary fibrosis (IPF)

• IPF is a severe, progressive lung disease with poor prognosis and limited treatment options; over 130,000 US patients and 3 million globally.

• PIPE-791 is a selective LPA1R antagonist showing sustained target engagement, favorable PK, and dose-dependent lung receptor occupancy.

• Preclinical models demonstrated reduced lung fibrosis and high receptor occupancy at low doses.

• Phase 1 trials showed no dose-limiting toxicities, favorable safety, and prolonged exposure.

• Phase 2 PROPEL-IPF trial initiated in December 2025, targeting 324 subjects with primary endpoint of FVC change at 26 weeks.

PIPE-791: Chronic pain

• LPA1R pathway implicated in neuropathic pain; significant patient populations in osteoarthritis and low back pain.

• Phase 1b trial in chronic osteoarthritis and lower back pain showed favorable safety and tolerability at 10mg QD.

• No serious adverse events or clinically meaningful changes in vital signs; most TEAEs were mild to moderate.

• Consistent numerical improvements in pain scores for both average and worst pain, with higher responder rates versus placebo.

• Data support further development for chronic pain indications.